The main goal of palliative care is to improve quality of life by treating symptoms in patients with life-threatening illnesses. Most patients suffer from more than five severe comorbidities in the last 6 months of life. However, for patients receiving palliative care, interventions to prevent possible long-term complications of these comorbidities are no longer the primary aim of care. This paper aimed to review the literature regarding decision making about medication for comorbid disease at the end of life, defined as a life expectancy <3 months, and to formulate preliminary recommendations based on the existing literature. An integrative review approach was used. We searched the MEDLINE, EMBASE, and CINAHL databases. Papers were included if they had been published in the English language between 1 January 1995 and 31 December 2013, with an abstract. Additional studies were identified by searching bibliographies. Factors to consider when systematically reviewing medications are the goals of care, remaining life expectancy, treatment targets, time until benefit, number needed to treat, number needed to harm, and adverse drug reactions. Existing research focuses particularly on the use of certain drug classes during end-of-life care, including statins, antihypertensive agents, anticoagulants, antihyperglycaemic agents and antibiotics. Based on the results of this review, we made preliminary recommendations for these medication groups. Medication that does not benefit the patient in any way should be avoided. The aim of medication at the end of life should be symptom control. There is a need for prospective trials to give further insight into the decision-making process of medication management at the end of life.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Koh NY, Koo WH. Polypharmacy in palliative care: can it be reduced? Singapore Med J. 2002;43(6):279–83.
Sepulveda C, Marlin A, Yoshida T, et al. Palliative care: the World Health Organization’s global perspective. J Pain Symptom Manag. 2002;24(2):91–6.
Hui D, Mori M, Parsons HA, et al. The lack of standard definitions in the supportive and palliative oncology literature. J Pain Symptom Manag. 2012;43(3):582–92.
Van Mechelen W, Aertgeerts B, De Ceulaer K, et al. Defining the palliative care patient: a systematic review. Palliat Med. 2013;27(3):197–208.
Unit EI, Britain G. The quality of death: ranking end-of-life care across the world. Economist Intelligence Unit; 2010.
Kierner KA, Gartner V, Schwarz M, et al. Use of thromboprophylaxis in palliative care patients: a survey among experts in palliative care, oncology, intensive care, and anticoagulation. Am J Hosp Palliat Care. 2008;25(2):127–31.
Currow DC, Stevenson JP, Abernethy AP, et al. Prescribing in palliative care as death approaches. J Am Geriatr Soc. 2007;55(4):590–5.
Nauck F, Ostgathe C, Klaschik E, et al. Drugs in palliative care: results from a representative survey in Germany. Palliat Med. 2004;18(2):100–7.
Sokol KC, Knudsen JF, Li MM. Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side-effect management. J Clin Pharm Ther. 2007;32(2):169–75.
Riechelmann RP, Tannock IF, Wang L, et al. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst. 2007;99(8):592–600.
Holmes HM. Rational prescribing for patients with a reduced life expectancy. Clin Pharmacol Ther. 2009;85(1):103–7.
Zeppetella G. How do terminally ill patients at home take their medication? Palliat Med. 1999;13(6):469–75.
Fede A, Miranda M, Antonangelo D, et al. Use of unnecessary medications by patients with advanced cancer: cross-sectional survey. Support Care Cancer. 2011;19(9):1313–8.
Riechelmann RP, Krzyzanowska MK, Zimmermann C. Futile medication use in terminally ill cancer patients. Support Care Cancer. 2009;17(6):745–8.
Stevenson J, Abernethy AP, Miller C, et al. Managing comorbidities in patients at the end of life. BMJ. 2004;329(7471):909–12.
Whittemore R, Knafl K. The integrative review: updated methodology. J Adv Nurs. 2005;52(5):546–53.
Disler RT, Currow DC, Phillips JL, et al. Interventions to support a palliative care approach in patients with chronic obstructive pulmonary disease: an integrative review. Int J Nurs Stud. 2012;49(11):1443–58.
Holmes HM, Hayley DC, Alexander GC, et al. Reconsidering medication appropriateness for patients late in life. Arch Intern Med. 2006;166(6):605–9.
Currow DC, Abernethy AP. Frameworks for approaching prescribing at the end of life. Arch Intern Med. 2006;166(21):2404.
Cruz-Jentoft AJ, Boland B, Rexach L. Drug therapy optimization at the end of life. Drugs Aging. 2012;29(6):511–21.
Fins JJ, Miller FG, Acres CA, et al. End-of-life decision-making in the hospital: current practice and future prospects. J Pain Symptom Manag. 1999;17(1):6–15.
McLean S, Sheehy-Skeffington B, O’Leary N, et al. Pharmacological management of co-morbid conditions at the end of life: is less more? Ir J Med Sci. 2012;182(1):107–12.
O’Mahony D, O’Connor MN. Pharmacotherapy at the end-of-life. Age Ageing. 2011;40(4):419–22.
Parsons C, Hughes CM, Passmore AP, et al. Withholding, discontinuing and withdrawing medications in dementia patients at the end of life: a neglected problem in the disadvantaged dying? Drugs Aging. 2010;27(6):435–49.
Riechelmann RP, Moreira F, Smaletz O, et al. Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol. 2005;56(3):286–90.
Stevenson JP, Currow DC, Abernethy AP. Frameworks for prescribing in comorbid illness. J Pain Symptom Manag. 2007;34(2):117–8.
Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003;163(22):2716–24.
Bain KT, Holmes HM, Beers MH, et al. Discontinuing medications: a novel approach for revising the prescribing stage of the medication-use process. J Am Geriatr Soc. 2008;56(10):1946–52.
Gallagher P, O’Mahony D. STOPP (Screening Tool of Older Persons’ potentially inappropriate Prescriptions): application to acutely ill elderly patients and comparison with Beers’ criteria. Age Ageing. 2008;37(6):673–9.
Spinewine A, Dumont C, Mallet L, et al. Medication appropriateness index: reliability and recommendations for future use. J Am Geriatr Soc. 2006;54(4):720–2.
Tjia J, Velten SJ, Parsons C, et al. Studies to reduce unnecessary medication use in frail older adults: a systematic review. Drugs Aging. 2013;30(5):285–307.
Suhrie EM, Hanlon JT, Jaffe EJ, et al. Impact of a geriatric nursing home palliative care service on unnecessary medication prescribing. Am J Geriatr Pharmacother. 2009;7(1):20–5.
Garfinkel D, Mangin D. Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: addressing polypharmacy. Arch Intern Med. 2010;170(18):1648–54.
Garfinkel D, Zur-Gil S, Ben-Israel J. The war against polypharmacy: a new cost-effective geriatric-palliative approach for improving drug therapy in disabled elderly people. Isr Med Assoc J. 2007;9(6):430–4.
Brandt NJ, Stefanacci RG. Discontinuation of unnecessary medications in older adults. Consult Pharm. 2011;26(11):845–54.
Silveira MJ, Kazanis AS, Shevrin MP. Statins in the last six months of life: a recognizable, life-limiting condition does not decrease their use. J Palliat Med. 2008;11(5):685–93.
Vollrath AM, Sinclair C, Hallenbeck J. Discontinuing cardiovascular medications at the end of life: lipid-lowering agents. J Palliat Med. 2005;8(4):876–81.
Bayliss EA, Bronsert MR, Reifler LM, et al. Statin prescribing patterns in a cohort of cancer patients with poor prognosis. J Palliat Med. 2013;16(4):412–8.
Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ. 2010;340:c2197.
Bottorff MB. Statin safety and drug interactions: clinical implications. Am J Cardiol. 2006;97(8A):27C–31C.
Davis GF. Discontinuing lipid-lowering agents. J Palliat Med. 2006;9(3):619 (author reply 21-2).
Vandenhaute V. Palliative care and type II diabetes: a need for new guidelines? Am J Hosp Palliat Care. 2010;27(7):444–5.
Ford-Dunn S, Smith A, Quin J. Management of diabetes during the last days of life: attitudes of consultant diabetologists and consultant palliative care physicians in the UK. Palliat Med. 2006;20(3):197–203.
Angelo M, Ruchalski C, Sproge BJ. An approach to diabetes mellitus in hospice and palliative medicine. J Palliat Med. 2011;14(1):83–7.
King EJ, Haboubi H, Evans D, et al. The management of diabetes in terminal illness related to cancer. QJM. 2012;105(1):3–9.
Tice MA. Diabetes management at the end of life: transitioning from tight glycemic control to comfort. Home Healthc Nurse. 2006;24(5):290–3.
Holmes HM, Bain KT, Zalpour A, et al. Predictors of anticoagulation in hospice patients with lung cancer. Cancer. 2010;116(20):4817–24.
Legault S, Tierney S, Senecal I, et al. Evaluation of a thromboprophylaxis quality improvement project in a palliative care unit. J Pain Symptom Manag. 2011;41(3):503–10.
Spiess JL. Can I stop the warfarin? A review of the risks and benefits of discontinuing anticoagulation. J Palliat Med. 2009;12(1):83–7.
Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol. 2004;22(10):1944–8.
Chambers JC. Prophylactic heparin in palliative care: … to a challenging idea. BMJ. 2006;332(7543):729.
Gillon S, Noble S, Ward J, et al. Primary thromboprophylaxis for hospice inpatients: who needs it? Palliat Med. 2011;25(7):701–5.
Soto-Cardenas MJ, Pelayo-Garcia G, Rodriguez-Camacho A, et al. Venous thromboembolism in patients with advanced cancer under palliative care: additional risk factors, primary/secondary prophylaxis and complications observed under normal clinical practice. Palliat Med. 2008;22(8):965–8.
Johnson MJ. Problems of anticoagulation within a palliative care setting: an audit of hospice patients taking warfarin. Palliat Med. 1997;11(4):306–12.
Johnson MJ, Sherry K. How do palliative physicians manage venous thromboembolism? Palliat Med. 1997;11(6):462–8.
Kirkova J, Fainsinger RL. Thrombosis and anticoagulation in palliative care: an evolving clinical challenge. J Palliat Care. 2004;20(2):101–4.
McLean S, Ryan K, O’Donnell JS. Primary thromboprophylaxis in the palliative care setting: a qualitative systematic review. Palliat Med. 2010;24(4):386–95.
Noble S. Management of venous thromboembolism in the palliative care setting. Int J Palliat Nurs. 2007;13(12):574–9.
Noble SI, Nelson A, Finlay IG. Factors influencing hospice thromboprophylaxis policy: a qualitative study. Palliat Med. 2008;22(7):808–13.
Noble SI, Hood K, Finlay IG. The use of long-term low-molecular weight heparin for the treatment of venous thromboembolism in palliative care patients with advanced cancer: a case series of sixty two patients. Palliat Med. 2007;21(6):473–6.
Noble S. The challenges of managing cancer related venous thromboembolism in the palliative care setting. Postgrad Med J. 2007;83(985):671–4.
Tran QN. Role of palliative low-molecular-weight heparin for treating venous thromboembolism in patients with advanced cancer. Am J Hosp Palliat Care. 2010;27(6):416–9.
Weber C, Merminod T, Herrmann FR, et al. Prophylactic anti-coagulation in cancer palliative care: a prospective randomised study. Support Care Cancer. 2008;16(7):847–52.
Stiel S, Krumm N, Pestinger M, et al. Antibiotics in palliative medicine: results from a prospective epidemiological investigation from the HOPE survey. Support Care Cancer. 2012;20(2):325–33.
Enck RE. Antibiotic use in end-of-life care: a soft line? Am J Hosp Palliat Care. 2010;27(4):237–8.
Oh DY, Kim JH, Kim DW, et al. Antibiotic use during the last days of life in cancer patients. Eur J Cancer Care (Engl). 2006;15(1):74–9.
Lam PT, Chan KS, Tse CY, et al. Retrospective analysis of antibiotic use and survival in advanced cancer patients with infections. J Pain Symptom Manag. 2005;30(6):536–43.
Chun ED, Rodgers PE, Vitale CA, et al. Antimicrobial use among patients receiving palliative care consultation. Am J Hosp Palliat Care. 2010;27(4):261–5.
White PH, Kuhlenschmidt HL, Vancura BG, et al. Antimicrobial use in patients with advanced cancer receiving hospice care. J Pain Symptom Manag. 2003;25(5):438–43.
Abduh Al-Shaqi M, Alami AH, Zahrani AS, et al. The pattern of antimicrobial use for palliative care in-patients during the last week of life. Am J Hosp Palliat Care. 2012;29(1):60–3.
Chen LK, Chou YC, Hsu PS, et al. Antibiotic prescription for fever episodes in hospice patients. Support Care Cancer. 2002;10(7):538–41.
Mirhosseini M, Oneschuk D, Hunter B, et al. The role of antibiotics in the management of infection-related symptoms in advanced cancer patients. J Palliat Care. 2006;22(2):69–74.
Oneschuk D, Fainsinger R, Demoissac D. Antibiotic use in the last week of life in three different palliative care settings. J Palliat Care. 2002;18(1):25–8.
Nagy-Agren S, Haley H. Management of infections in palliative care patients with advanced cancer. J Pain Symptom Manag. 2002;24(1):64–70.
Pereira J, Watanabe S, Wolch G. A retrospective review of the frequency of infections and patterns of antibiotic utilization on a palliative care unit. J Pain Symptom Manag. 1998;16(6):374–81.
Vitetta L, Kenner D, Sali A. Bacterial infections in terminally ill hospice patients. J Pain Symptom Manag. 2000;20(5):326–34.
Thompson AJ, Silveira MJ, Vitale CA, et al. Antimicrobial use at the end of life among hospitalized patients with advanced cancer. Am J Hosp Palliat Care. 2012;29(8):599–603.
Ballentine NH. Polypharmacy in the elderly: maximizing benefit, minimizing harm. Crit Care Nurs Q. 2008;31(1):40–5.
Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333(20):1301–7.
Noble SI, Nelson A, Turner C, et al. Acceptability of low molecular weight heparin thromboprophylaxis for inpatients receiving palliative care: qualitative study. BMJ. 2006;332(7541):577–80.
Clayton J, Fardell B, Hutton-Potts J, et al. Parenteral antibiotics in a palliative care unit: prospective analysis of current practice. Palliat Med. 2003;17(1):44–8.
Cannon KT, Choi MM, Zuniga MA. Potentially inappropriate medication use in elderly patients receiving home health care: a retrospective data analysis. Am J Geriatr Pharmacother. 2006;4(2):134–43.
Nguyen JK, Fouts MM, Kotabe SE, et al. Polypharmacy as a risk factor for adverse drug reactions in geriatric nursing home residents. Am J Geriatr Pharmacother. 2006;4(1):36–41.
Zarowitz BJ, Stebelsky LA, Muma BK, et al. Reduction of high-risk polypharmacy drug combinations in patients in a managed care setting. Pharmacotherapy. 2005;25(11):1636–45.
Koopmans RT, Lavrijsen JC, Hoek JF, et al. Dutch elderly care physician: a new generation of nursing home physician specialists. J Am Geriatr Soc. 2010;58(9):1807–9.
Di Giulio P, Toscani F, Villani D, et al. Dying with advanced dementia in long-term care geriatric institutions: a retrospective study. J Palliat Med. 2008;11(7):1023–8.
Hoek JF, Ribbe MW, Hertogh CM, et al. The role of the specialist physician in nursing homes: the Netherlands’ experience. Int J Geriatr Psychiatry. 2003;18(3):244–9.
Arnold EM. The cessation of cancer treatment as a crisis. Soc Work Healthc. 1999;29(2):21–38.
No sources of funding were used to assist in the preparation of this review. Ronald T.C.M. van Nordennen, Jan Lavrijsen, Kris Vissers and Raymond Koopmans have no potential conflicts of interest that are directly relevant to the content of this review.
About this article
Cite this article
van Nordennen, R.T.C.M., Lavrijsen, J.C.M., Vissers, K.C.P. et al. Decision Making About Change of Medication for Comorbid Disease at the End of Life: An Integrative Review. Drugs Aging 31, 501–512 (2014). https://doi.org/10.1007/s40266-014-0182-4
- Palliative Care
- Deep Vein Thrombosis
- Antihypertensive Agent
- Medication Group
- Comorbid Disease